Metformin And Probiotics Synergy
Background
The prevalence of type 2 diabetes mellitus is on a relentless rise, emerging as a critical global health concern. This metabolic disorder hinges on the body’s inability to either respond to insulin adequately or produce it in sufficient quantities.
The consequence is elevated blood glucose levels, which, when prolonged, unleash havoc on various organ systems, including the circulatory and nervous systems.
The genesis and progression of type 2 diabetes mellitus stem from an intricate interplay of metabolic, genetic, and environmental factors.
Tip: Fill out this form to check if you or a friend qualify for CGMs
However, even amidst genetic predisposition, modifiable risk factors, such as dietary choices and lifestyle, offer avenues for effective disease management.
A mounting body of evidence underscores the pivotal role of the gut microbiome in health and disease.
Dysbiosis, an imbalance in the gut microbiome, has been implicated in a range of disorders affecting multiple organ systems, including the development of type 2 diabetes mellitus.
The abundance and diversity of gut microflora play a substantial role in the host’s glycemic regulation.
Must Read CGMs in noncritical care hospitals optimizes glycemic control
Harnessing prebiotics and probiotics to reshape the gut microbiome has been a subject of extensive research for disease management.
About the Study
In this comprehensive study, researchers delved into clinical trials exploring the potential of oral probiotics in managing type 2 diabetes mellitus and scrutinized the composition of probiotics and interventions involving probiotic combinations.
The gut microbiome is intricately connected with critical physiological processes like immunity and nutrient absorption.
Research in non-human mammalian models has unequivocally established the profound interplay between metabolic disorders and the gut microbiome. However, the human evidence supporting this link remains debated.
Thus, only completed human clinical trials were considered for this review, with those conducted on animal models and meta-analyses being excluded.
The trials incorporated in the review encompassed diverse aspects of type 2 diabetes mellitus, including lipid profiles, glycemic metabolism, cardiovascular factors, fecal analysis, and inflammation.
Prediabetic patients and comorbidity analyses were not part of the study’s scope. Additionally, studies involving non-oral probiotics and participants below the age of 18 were excluded.
Also, Read About CGM and WeightWatchers
The researchers gathered data encompassing the clinical trial type, participant age, and participant count.
They also cataloged details about the probiotic intervention, such as daily colony forming units administered, intervention duration, administration frequency, probiotic composition, strain count, genus-level identification of microbe species, and placebo usage.
The examined outcomes spanned parameters linked to glycemic and lipid levels, kidney and cardiovascular indicators, anthropometric measurements, oxidative stress, inflammation indicators, and fecal analysis.
Results
The findings unveiled that approximately 64% of the studies within the review documented improvements in at least one parameter tied to glycemic levels. Simultaneously, 45% of the studies reported enhancements in at least one parameter related to lipid levels subsequent to oral probiotic administration.
However, none of the studies revealed uniform improvements across all lipid and glycemic parameters or blood pressure.
The diverse composition, dosage, and duration of probiotic interventions potentially accounted for the divergent findings in these studies.
Notably, the co-administration of oral probiotics with metformin treatment demonstrated a notable improvement in glycemic control among type 2 diabetes patients.
Findings regarding the global effects of probiotic interventions on inflammation remained inconclusive, although a few studies noted enhancements in systolic blood pressure correlated with probiotic interventions.
Conclusions
In the grander scheme, the findings suggest that the administration of probiotic interventions to enhance gut microbiota in type 2 diabetes patients doesn’t trigger adverse reactions.
For individuals undergoing metformin treatment, it notably augments glycemic control. However, further clinical trials and research are imperative to unravel specific factors, such as the impact of distinct microbial strains and optimal probiotic intervention dosages, in enhancing outcomes for type 2 diabetes patients.
